Why Early Safety Profiling Matters: Visualizing Risk Before It Reaches the Clinic

In the early stages of drug discovery, one of the biggest challenges is identifying potential safety risks before a compound ever reaches a patient. Adverse drug reactions (ADRs) are a leading cause of clinical trial failures, regulatory delays, and market withdrawals. But what if you could visualize those risks—before investing millions in development?

At Eurofins Discovery, we’ve developed a powerful tool called In Vitro Safety Insight that helps researchers do just that. By combining secondary pharmacology screening with intuitive data visualization, this platform enables early identification of organ systems at risk due to off-target activity—giving teams a clearer picture of a compound’s safety profile from the start.

The Problem: Hidden Risks in Target Modulation

When a drug interacts with unintended targets, it can trigger a cascade of adverse effects. These off-target interactions are often subtle and difficult to detect using traditional methods. Even with access to public databases and literature, interpreting the relevance of these interactions to human safety remains a complex task.

Secondary pharmacology screening is designed to address this, but raw data alone isn’t enough. What’s needed is a way to translate that data into actionable insights—something that can guide decisions about which compounds to prioritize, which to modify, and which to drop.

The Solution: Organ System Hazard Metric Profile (OSHMP)

In Vitro Safety Insight introduces the Organ System Hazard Metric Profile (OSHMP)—a visualization that maps pharmacological activity to potential adverse events across organ systems. It integrates data from multiple sources, including literature, databases, and experimental assays, and scores each target-organ pair based on the strength of evidence and degree of inhibition.

The result is a radar-style plot that highlights which organs may be at risk, helping researchers quickly assess the safety implications of a compound’s target profile.

Why It Matters for You

If you’re in early-stage drug discovery, this tool can help you:

• Spot red flags early—before investing in costly preclinical or clinical studies.
• Compare compounds side-by-side to identify safer alternatives within the same class.
• Design smarter follow-up studies based on specific organ system risks.
• Communicate safety data clearly across teams and stakeholders.

Whether you’re working on CNS drugs, cardiovascular agents, or any other therapeutic area, understanding the safety landscape early can save time, money, and lives.

Ready to Explore?

If you’re just beginning to explore how to improve safety profiling in your pipeline, In Vitro Safety Insight offers a compelling starting point. It’s not just about data—it’s about clarity, confidence, and making informed decisions from day one.